Analysis of vaccine-induced T cells in humans with cancer.
Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means ofeliciting tumor-specific immune responses to mediate tumor regression and clearance. Developing vaccines targeted against cancer became an important focus as a therapy following the success of viral vaccines in preventing infection and disease. In humans with cancer, similar to viral infections, the host immune system is capable of recognizing antigens expressed on tumor cells. This similarity allows the immunological framework of the viral vaccine to be adapted to the cancer setting in hopes of enhancing human T-cell reactivity against tumor. It is generally believed that a requirement for tumor destruction to occur is the induction of sufficient levels of immune cells with high avidity for recognition of tumor antigens. Moreover, the cells must be targeted to the tumor site and be capable of infiltrating tumor stroma.2 Several tumor-associated antigens (TAA) have been identified in the melanoma model which has allowed for immunization trials to evaluate therapeutic potential of tumor-specific T-cell induction. Some clinical trials reported limited success ofT-cell mediated tumor rejection, reportingpartial or complete regression in 10 to 30% of patients. Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specific T-cell induction indeed occurs but alone is not adequate to induce tumor regression. Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means ofeliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion.
Slezak
Stefanie L
SL
Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Worschech
Andrea
A
Wang
Ena
E
Stroncek
David F
DF
Marincola
Francesco M
FM
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D016233:Immunotherapy, Active; D008213:Lymphocyte Activation / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
Blood. 1995 Aug 15;86(4):1408-19
7632949
J Immunother. 2002 Mar-Apr;25(2):97-138
12074049
Nature. 2000 Aug 3;406(6795):536-40
10952317
J Transl Med. 2007 Mar 28;5:17
17391521
Genome Biol. 2007;8(1):R8
17222352
J Immunol Methods. 1998 Mar 1;212(1):89-98
9671156
Cancer Res. 2004 Oct 15;64(20):7279-87
15492247
Adv Immunol. 2000;74:181-273
10605607
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Int J Cancer. 2003 Jun 10;105(2):210-6
12673681
Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80
15580242
J Transl Med. 2006 Nov 27;4:50
17129373
Cells Tissues Organs. 2004;177(3):124-31
15388986
Nat Immunol. 2002 Nov;3(11):999-1005
12407407
Prog Exp Tumor Res. 1970;13:1-27
4921480
Science. 2002 Oct 25;298(5594):850-4
12242449
J Immunol. 2000 Aug 15;165(4):2287-96
10925318
Science. 1996 Oct 4;274(5284):94-6
8810254
Urology. 1989 Feb;33(2):141-4
2916288
J Immunol. 2001 May 1;166(9):5817-25
11313426
Nat Med. 2004 Sep;10(9):909-15
15340416
N Engl J Med. 2003 Jul 10;349(2):125-38
12853585
J Transl Med. 2004 Oct 15;2(1):34
15488140
Nat Immunol. 2002 Nov;3(11):991-8
12407406
J Immunother. 2007 Jul-Aug;30(5):533-43
17589294
J Urol. 2003 Jul;170(1):178-9
12796677
Semin Cancer Biol. 2003 Dec;13(6):473-80
15001166
Lancet Oncol. 2004 Nov;5(11):681-9
15522656
J Immunol. 1999 Dec 15;163(12):6867-75
10586088
Nature. 2001 Apr 26;410(6832):1107-11
11323675
Cell. 2002 Dec 13;111(6):837-51
12526810
Semin Cancer Biol. 2003 Dec;13(6):461-72
15001165
Genome Biol. 2002 Jun 25;3(7):RESEARCH0035
12184809
J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):266-77
8877721
Clin Cancer Res. 2007 Jul 1;13(13):3776-82
17606707
J Immunol. 2002 Jan 1;168(1):338-47
11751979
Blood. 2004 Oct 1;104(7):1970-8
15187028
Immunity. 2004 Aug;21(2):137-48
15308095
J Immunol. 1999 Dec 1;163(11):6292-300
10570323
J Immunol. 2008 Feb 1;180(3):1362-72
18209030
Eur J Cancer. 2006 Jul;42(10):1322-30
16737813
Lancet. 2008 Mar 1;371(9614):771-83
18275997
Cancer Immunol Immunother. 2007 Jul;56(7):1047-63
17124584
J Immunother. 2008 Jan;31(1):101-12
18157017
Cancer Res. 2002 Jul 1;62(13):3581-6
12097256
J Transl Med. 2008 Apr 15;6:17
18412971
J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44
10944556
Trends Immunol. 2003 Jun;24(6):335-42
12810110
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2346s-2352s
16609057
Expert Opin Biol Ther. 2008 Mar;8(3):337-49
18294104
Immunity. 2008 Jul 18;29(1):9-11
18631452
Curr Opin Immunol. 2005 Aug;17(4):423-7
15950448
J Natl Cancer Inst. 2002 Jun 5;94(11):805-18
12048268
Annu Rev Immunol. 2004;22:329-60
15032581
PLoS Med. 2005 Oct;2(10):e265
16162034
J Transl Med. 2004 Jun 2;2(1):17
15175100
Eur J Cancer. 2006 May;42(8):1031-9
16616487
Int J Cancer. 1998 Dec 9;78(6):699-706
9833762
Clin Cancer Res. 2005 Jan 1;11(1):113-22
15671535
Am J Clin Oncol. 1997 Aug;20(4):416-8
9256902
Trends Immunol. 2008 Jun;29(6):256-62
18457994
J Transl Med. 2005 Apr 14;3(1):16
15831096
J Exp Med. 1997 Aug 29;186(5):645-53
9271580